Tvardi Therapeutics Q1 Earnings Report Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 51 minutes ago
0mins
Should l Buy TVRD?
Source: seekingalpha
- Earnings Miss: Tvardi Therapeutics reported a Q1 GAAP EPS of -$0.73, missing expectations by $0.04, indicating challenges in profitability that could undermine investor confidence.
- Cash Position: As of March 31, 2026, the company's cash, cash equivalents, and short-term investments totaled $25.0 million, down from $30.8 million as of December 31, 2025, reflecting increased liquidity pressure.
- Funding Strategy: Tvardi anticipates that its current cash runway is sufficient to fund operations through clinical readouts and into Q4 2026, indicating a cautious approach to financial management amid future challenges.
- Market Outlook: Despite financial pressures, Tvardi is actively advancing clinical trials, and successful clinical readouts could present new growth opportunities, enhancing the company's competitive position in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TVRD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TVRD
Wall Street analysts forecast TVRD stock price to rise
6 Analyst Rating
2 Buy
4 Hold
0 Sell
Moderate Buy
Current: 3.660
Low
4.00
Averages
9.00
High
15.00
Current: 3.660
Low
4.00
Averages
9.00
High
15.00
About TVRD
Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tvardi Therapeutics Q1 Earnings Report Analysis
- Earnings Miss: Tvardi Therapeutics reported a Q1 GAAP EPS of -$0.73, missing expectations by $0.04, indicating challenges in profitability that could undermine investor confidence.
- Cash Position: As of March 31, 2026, the company's cash, cash equivalents, and short-term investments totaled $25.0 million, down from $30.8 million as of December 31, 2025, reflecting increased liquidity pressure.
- Funding Strategy: Tvardi anticipates that its current cash runway is sufficient to fund operations through clinical readouts and into Q4 2026, indicating a cautious approach to financial management amid future challenges.
- Market Outlook: Despite financial pressures, Tvardi is actively advancing clinical trials, and successful clinical readouts could present new growth opportunities, enhancing the company's competitive position in the market.
See More
Tvardi Reports Clinical Progress on TTI-109 Inhibitor
- TTI-109 Study Progress: Tvardi is conducting a healthy volunteer study for TTI-109, with topline data expected in June 2026, which will inform future clinical development strategies and enhance the company's competitive edge in the STAT3 inhibitor market.
- TTI-101 Clinical Trials: The Phase 1b/2 trial of TTI-101 for hepatocellular carcinoma is on track to report topline results in the second half of 2026, with prior interim findings indicating clinically meaningful activity across various treatment settings, potentially opening new market opportunities for the company.
- Financial Status Improvement: Research and development expenses for Q1 2026 were $4.9 million, up from $3.1 million in Q1 2025, primarily due to increased costs associated with TTI-109 development, reflecting the company's ongoing investment in advancing its product pipeline.
- Cash Flow Outlook: As of March 31, 2026, Tvardi reported cash and short-term investments of $25 million, which is expected to be sufficient to fund operations through Q4 2026, ensuring adequate liquidity ahead of clinical readouts and boosting investor confidence.
See More
Tvardi Therapeutics Reports 2025 Financial Results and Pipeline Progress
- Improved Financial Performance: Tvardi Therapeutics reported a net loss of $7.3 million for Q4 2025, translating to a diluted loss of $0.78 per share, which is a significant improvement from the $12.7 million loss and $4.94 per share in the same quarter of 2024, indicating progress in cost management and operational efficiency.
- Significant Clinical Progress: The company's STAT3-targeted pipeline, including TTI-109 and TTI-101, is advancing towards multiple key clinical milestones in 2026, with TTI-101 showing clinically meaningful activity in the REVERT LIVER CANCER trial, enhancing investor confidence in its future potential.
- Stable Cash Flow: Tvardi ended 2025 with $30.8 million in cash and short-term investments, expected to fund operations into Q4 2026, ensuring financial stability during the upcoming clinical data readouts.
- Equity Structure Adjustment: The company implemented a 1-for-3 reverse stock split on April 14, 2025, aimed at enhancing stock liquidity and market appeal, although the stock price fell by 0.62% to $3.18 on Tuesday, which may impact investor sentiment.
See More
Tvardi Therapeutics Q4 Earnings Miss Expectations
- Earnings Performance: Tvardi Therapeutics reported a Q4 GAAP EPS of -$0.78, missing expectations by $0.19, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of December 31, 2025, Tvardi's cash, cash equivalents, and short-term investments totaled $30.8 million, down from $31.6 million in the same period of 2024, reflecting pressure on the company's financial management.
- Funding Strategy: The company anticipates that its current cash runway will be sufficient to fund operations as planned through clinical readouts into Q4 2026, indicating a cautious approach to cash utilization to ensure ongoing operations.
- Future Outlook: Despite financial challenges, Tvardi plans to enhance its market position through advancing clinical trials, which, if successful, could present new growth opportunities for the company.
See More
Tvardi to Present TTI-101 Clinical Data at 44th J.P. Morgan Healthcare Conference
- Clinical Trial Progress: Tvardi Therapeutics will present new Phase 2 REVERT IPF clinical trial data for TTI-101 at the 44th J.P. Morgan Healthcare Conference on January 15, 2026, demonstrating encouraging signals across fibrosis, inflammatory markers, and pulmonary function, further supporting TTI-101's efficacy in inhibiting STAT3.
- Market Demand Alignment: TTI-101, an innovative therapy targeting fibrosis-driven diseases, addresses the urgent need for effective treatment options in the clinical landscape, potentially bolstering the company's market position in the biopharmaceutical sector.
- Investor Engagement: The conference will provide a webcast for investors to access detailed information about TTI-101, likely attracting increased investor interest in Tvardi's clinical advancements and future potential.
- Strategic Positioning: Tvardi's focus on developing small molecule therapies targeting STAT3 highlights its strategic importance in addressing unmet medical needs in fibrosis diseases, which may present long-term growth opportunities for the company.
See More
Tvardi Therapeutics Shares Plunge 80% Following Disappointing Phase 2 Trial Data
- Stock Plunge: Tvardi Therapeutics experienced an over 80% drop in share price on October 13, 2025, following disappointing preliminary data from its Phase 2 REVERT clinical trial, which is likely to severely impact investor confidence and may lead to further legal actions.
- Trial Failure: The trial aimed to assess the safety and efficacy of TTI-101 in patients with idiopathic pulmonary fibrosis, but preliminary results indicated that it did not meet its goals, potentially affecting the company's future R&D direction and funding inflow.
- Investor Losses: Faruqi & Faruqi LLP is investigating potential claims against Tvardi, encouraging investors who suffered significant losses to reach out, highlighting the legal risks that could exacerbate the financial pressures faced by the company.
- Market Reaction: The poor clinical trial results may lead to substantial losses for Tvardi's shareholders, further impacting the company's reputation and market position within the biopharmaceutical industry.
See More
Tvardi Therapeutics Q1 Earnings Report Analysis
- Earnings Miss: Tvardi Therapeutics reported a Q1 GAAP EPS of -$0.73, missing expectations by $0.04, indicating challenges in profitability that could undermine investor confidence.
- Cash Position: As of March 31, 2026, the company's cash, cash equivalents, and short-term investments totaled $25.0 million, down from $30.8 million as of December 31, 2025, reflecting increased liquidity pressure.
- Funding Strategy: Tvardi anticipates that its current cash runway is sufficient to fund operations through clinical readouts and into Q4 2026, indicating a cautious approach to financial management amid future challenges.
- Market Outlook: Despite financial pressures, Tvardi is actively advancing clinical trials, and successful clinical readouts could present new growth opportunities, enhancing the company's competitive position in the market.
See More
Tvardi Reports Clinical Progress on TTI-109 Inhibitor
- TTI-109 Study Progress: Tvardi is conducting a healthy volunteer study for TTI-109, with topline data expected in June 2026, which will inform future clinical development strategies and enhance the company's competitive edge in the STAT3 inhibitor market.
- TTI-101 Clinical Trials: The Phase 1b/2 trial of TTI-101 for hepatocellular carcinoma is on track to report topline results in the second half of 2026, with prior interim findings indicating clinically meaningful activity across various treatment settings, potentially opening new market opportunities for the company.
- Financial Status Improvement: Research and development expenses for Q1 2026 were $4.9 million, up from $3.1 million in Q1 2025, primarily due to increased costs associated with TTI-109 development, reflecting the company's ongoing investment in advancing its product pipeline.
- Cash Flow Outlook: As of March 31, 2026, Tvardi reported cash and short-term investments of $25 million, which is expected to be sufficient to fund operations through Q4 2026, ensuring adequate liquidity ahead of clinical readouts and boosting investor confidence.
See More
Tvardi Therapeutics Reports 2025 Financial Results and Pipeline Progress
- Improved Financial Performance: Tvardi Therapeutics reported a net loss of $7.3 million for Q4 2025, translating to a diluted loss of $0.78 per share, which is a significant improvement from the $12.7 million loss and $4.94 per share in the same quarter of 2024, indicating progress in cost management and operational efficiency.
- Significant Clinical Progress: The company's STAT3-targeted pipeline, including TTI-109 and TTI-101, is advancing towards multiple key clinical milestones in 2026, with TTI-101 showing clinically meaningful activity in the REVERT LIVER CANCER trial, enhancing investor confidence in its future potential.
- Stable Cash Flow: Tvardi ended 2025 with $30.8 million in cash and short-term investments, expected to fund operations into Q4 2026, ensuring financial stability during the upcoming clinical data readouts.
- Equity Structure Adjustment: The company implemented a 1-for-3 reverse stock split on April 14, 2025, aimed at enhancing stock liquidity and market appeal, although the stock price fell by 0.62% to $3.18 on Tuesday, which may impact investor sentiment.
See More
Tvardi Therapeutics Q4 Earnings Miss Expectations
- Earnings Performance: Tvardi Therapeutics reported a Q4 GAAP EPS of -$0.78, missing expectations by $0.19, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of December 31, 2025, Tvardi's cash, cash equivalents, and short-term investments totaled $30.8 million, down from $31.6 million in the same period of 2024, reflecting pressure on the company's financial management.
- Funding Strategy: The company anticipates that its current cash runway will be sufficient to fund operations as planned through clinical readouts into Q4 2026, indicating a cautious approach to cash utilization to ensure ongoing operations.
- Future Outlook: Despite financial challenges, Tvardi plans to enhance its market position through advancing clinical trials, which, if successful, could present new growth opportunities for the company.
See More
Tvardi to Present TTI-101 Clinical Data at 44th J.P. Morgan Healthcare Conference
- Clinical Trial Progress: Tvardi Therapeutics will present new Phase 2 REVERT IPF clinical trial data for TTI-101 at the 44th J.P. Morgan Healthcare Conference on January 15, 2026, demonstrating encouraging signals across fibrosis, inflammatory markers, and pulmonary function, further supporting TTI-101's efficacy in inhibiting STAT3.
- Market Demand Alignment: TTI-101, an innovative therapy targeting fibrosis-driven diseases, addresses the urgent need for effective treatment options in the clinical landscape, potentially bolstering the company's market position in the biopharmaceutical sector.
- Investor Engagement: The conference will provide a webcast for investors to access detailed information about TTI-101, likely attracting increased investor interest in Tvardi's clinical advancements and future potential.
- Strategic Positioning: Tvardi's focus on developing small molecule therapies targeting STAT3 highlights its strategic importance in addressing unmet medical needs in fibrosis diseases, which may present long-term growth opportunities for the company.
See More
Tvardi Therapeutics Shares Plunge 80% Following Disappointing Phase 2 Trial Data
- Stock Plunge: Tvardi Therapeutics experienced an over 80% drop in share price on October 13, 2025, following disappointing preliminary data from its Phase 2 REVERT clinical trial, which is likely to severely impact investor confidence and may lead to further legal actions.
- Trial Failure: The trial aimed to assess the safety and efficacy of TTI-101 in patients with idiopathic pulmonary fibrosis, but preliminary results indicated that it did not meet its goals, potentially affecting the company's future R&D direction and funding inflow.
- Investor Losses: Faruqi & Faruqi LLP is investigating potential claims against Tvardi, encouraging investors who suffered significant losses to reach out, highlighting the legal risks that could exacerbate the financial pressures faced by the company.
- Market Reaction: The poor clinical trial results may lead to substantial losses for Tvardi's shareholders, further impacting the company's reputation and market position within the biopharmaceutical industry.
See More
